Benzinga | Sep 10, 2021 09:25AM EDT

Neurocrine Biosciences To Present New INGREZZA (valbenazine) And ONGENTYS (opicapone) Data At MDS Virtual Congress 2021

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) and Parkinson's disease at the International Parkinson and Movement Disorder Society's (MDS) Virtual Congress 2021 being held September 17--22, 2021.

Data include a post hoc analysis from KINECT 4, a long-term Phase 3 study, demonstrating robust clinically meaningful reductions in TD symptoms at 48 weeks with once-daily INGREZZA(r) (valbenazine) capsules. Data show some patients met the criteria for TD remission within one year of once-daily INGREZZA treatment. Additionally, an oral presentation will introduce a new pooled data analysis from the BIPARK-1 and BIPARK-2 Phase 3 studies evaluating effects on sleep of ONGENTYS(r) (opicapone) compared to placebo in people with Parkinson's disease and motor fluctuations. Further, a poster presentation will feature new data from a Phase 1 open-label study assessing the effect of ONGENTYS on levodopa levels when administered as a once-daily add-on therapy to oral levodopa/carbidopa extended-release capsules, the first study to evaluate both formulations together.

"We look forward to sharing data that helps further characterize the real-world experience of patients treated with INGREZZA and ONGENTYS with the movement disorder neurology community," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. "The analyses presented reflect our commitment to better understanding the unmet needs of individuals living with the complex and debilitating disorders of tardive dyskinesia and Parkinson's disease."

Presentations include:

INGREZZA -- Tardive Dyskinesia

* Impacts of Tardive Dyskinesia (TD) Symptoms on Patients: Analysis of a TD-Specific Patient-Reported Outcome (Poster # 89)

* Patterns of Improvement with Valbenazine in Patients with Tardive Dyskinesia (Poster # 346)

* Reanalysis of a Patient-Reported Outcome (Tardive Dyskinesia Impact Scale) Shows Positive Results (Poster # 88)

ONGENTYS -- Parkinson's Disease (in collaboration with BIAL)

* Effects of Opicapone on Sleep Patterns in Patients with Parkinson's Disease and Motor Fluctuations (Poster # 396)

* Effects of Once-Daily Opicapone 50 mg on the Pharmacokinetics of Levodopa Administered as Carbidopa/Levodopa Extended-Release Capsules: An Open-Label Phase 1 Study (Poster # 507)

* Evaluating Patients' Preferences for Parkinson's Disease Treatments (Poster # 337)

* A Longitudinal Real-World Study of Opicapone in Patients with Parkinson's Disease and Motor Fluctuations (Poster # 410)

A full list of all abstracts being presented by Neurocrine Biosciences at the MDS Virtual Congress 2021 are available here.